Today, PAXMAN publishes a special issue of its newsletter aimed at shareholders, investors and other interested parties.
This issue focuses on the decision by the National Comprehensive Cancer Network® (NCCN®) to include scalp cooling as a recommended category 2A treatment to prevent alopecia for ovarian cancer patients. Since the NCCN included a corresponding recommendation for breast cancer patients in 2019, PAXMAN has seen an increasing patient enrolment in the US, and the company now expects a similar, albeit less substantial, positive effect.
In this issue, PAXMAN also outlines the company’s forceful, temporary program to reduce its operational costs as a pre-emptive measure due to lower demand for Q2 2020 caused by the coronavirus situation. However, the company has seen strong sales throughout Q1 2020, and has not seen any drop in patient enrolments in the US so far.
To read the newsletter, and subscribe to receive upcoming issues, follow this link:
https://bit.ly/paxapr20xen
PAXMAN’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on PAXMANs website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.
For more information, please contact:
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se
About PAXMAN
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four,
The PAXMAN share is listed on Nasdaq First North.
© Modular Finance, source